NexPlasmaGen key facts
as of Oct 2026- Developer of cold plasma delivery system designed to reduce cancer recurrence.
- NexPlasmaGen is valued at approximately $6.6M as of Oct 2026 (last reported valuation).
- It has raised $960K; the latest was Later Stage VC ($360K) in Dec 2025.
- Notable investors include Government of Quebec, Kettlebeck Ventures, Aligo Innovation, Andy Ortaaslan, Campus des technologies de la santé — 25 tracked in total.
- Status: Privately Held (backing).
NexPlasmaGen's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·The complete investor list: 25 names
- ·Watch NexPlasmaGen: the Monday email on marks, rounds and moves
NexPlasmaGen funding rounds
No funding rounds for NexPlasmaGen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs NexPlasmaGen
25+NexPlasmaGen valuation
NexPlasmaGen's last reported valuation was $6.6 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
NexPlasmaGen investors
25 investors are on record for NexPlasmaGen, including Government of Quebec, Kettlebeck Ventures, Aligo Innovation and Andy Ortaaslan.
About NexPlasmaGen
Developer of cold plasma delivery system designed to reduce cancer recurrence. The company's patented cold plasma device generates plasma species, producing cellular oxidative stress that kills cancer cells while sparing healthy tissue, enabling oncologist surgeons to reduce cancer recurrence after breast-conserving therapy and striving to reduce hospital direct costs while improving patient quality of life.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2008
- Employees
- 3
- Website
- nexplasmagen.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.